DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom The above ...

While other automated dosing algorithms typically require a doctor to program certain starting parameters, Beta Bionics’ iLet Bionic Pancreas needs only a user’s body weight to begin calculating ...

Dexcom said it is working with insulin pump manufacturers to integrate its new G7 sensor into current and future automated artificial pancreas systems. (Dexcom) Dexcom has obtained European approval ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Add Yahoo as a preferred source to see more of our stories on Google. The Dexcom G7 Continuous Glucose Monitoring (CGM) System, shown here with an iPhone and an Apple Watch. Dexcom warned patients ...

Add Yahoo as a preferred source to see more of our stories on Google. May 26 (Reuters) - Medical device maker Dexcom said on Tuesday some of its glucose ‌sensors slated for destruction were instead ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...